Literature DB >> 31179299

Clinical manifestations of Wilson disease in organs other than the liver and brain.

Karolina Dzieżyc-Jaworska1, Tomasz Litwin1, Anna Członkowska1,2.   

Abstract

Wilson disease (WD) is an inherited genetic disorder that is caused by copper metabolism disturbances with main hepatic, neurological, and psychiatric presentation. Deposits of copper accumulate in different organs and may cause a broad range of clinical manifestations. Patients with WD may present with ophthalmological symptoms, or renal, cardiac and osteoarticular involvement. The most common ophthalmological sign as a result of copper accumulation is the Kayser-Fleischer corneal ring, whereas sunflower cataracts are observed rarely. Retinal degeneration, present in WD patients, may serve as a marker of neurodegeneration. Osteoarticular involvement is quite common and includes osteopenia, osteoporosis and arthropathy, which may lead to bone fractures and joint problems mainly affecting knees and wrists. Renal disturbances include tubular dysfunction and renal calculi. A recent cardiac study has shown a higher risk of atrial fibrillation and heart failure in WD patients than in non-WD patients. Autonomic system dysfunction is also observed, but involvement is subclinical in most cases. Another manifestation of WD concerns endocrine system disturbances, which can lead to recurrent abortions, infertility, growth disruption, and parathyroid failure. However, it is possible to become pregnant for females with mild WD symptoms and for those who are compliant with therapy. Hematologic disturbances are frequent and may include acute hemolytic anemia, leucopenia, anemia and low platelet count. Other observed symptoms include lipomas and characteristic of WD skin changes like hyperpigmentation of the legs, xerosis or azure lunulae of the nails. In this paper, we present some of the less common, but nevertheless, important manifestations of WD.

Entities:  

Keywords:  Wilson disease (WD); cardiac disturbances; copper toxicity; endocrinologic manifestations; ophthalmologic signs; renal involvement

Year:  2019        PMID: 31179299      PMCID: PMC6531658          DOI: 10.21037/atm.2019.03.30

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  58 in total

1.  Effect of penicillamine on the kidney.

Authors:  A M Davison; A T Day; J R Golding; D Thomson
Journal:  Proc R Soc Med       Date:  1977

2.  The Kayser-Fleischer ring; a histochemical and electron microscope study.

Authors:  L L UZMAN; M A JAKUS
Journal:  Neurology       Date:  1957-05       Impact factor: 9.910

3.  Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease.

Authors:  D Hegedus; V Ferencz; P L Lakatos; S Meszaros; P Lakatos; C Horvath; F Szalay
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

4.  Procreation ability in Wilson's disease.

Authors:  B Tarnacka; M Rodo; S Cichy; A Członkowska
Journal:  Acta Neurol Scand       Date:  2000-06       Impact factor: 3.209

5.  Collagen cross-linking. Effect of D-penicillamine on cross-linking in vitro.

Authors:  R C Siegel
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

6.  Increased p-wave duration and p-wave dispersion in patients with aortic stenosis.

Authors:  Hasan Turhan; Ertan Yetkin; Ramazan Atak; Tayfun Altinok; Kubilay Senen; Mehmet Ileri; Hatice Sasmaz; Sengul Cehreli; Emine Kutuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

7.  Cardiac involvement in Wilson disease.

Authors:  Z Hlubocká; Z Marecek; A Linhart; E Kejková; L Pospísilová; P Martásek; M Aschermann
Journal:  J Inherit Metab Dis       Date:  2002-08       Impact factor: 4.982

8.  Autonomic dysfunction in Wilson's disease --a clinical and electrophysiological study.

Authors:  Salvadeeswaran Meenakshi-Sundaram; Arun B Taly; Vikram Kamath; G R Arunodaya; Shivaji Rao; H S Swamy
Journal:  Clin Auton Res       Date:  2002-06       Impact factor: 4.435

Review 9.  Copper toxicity, oxidative stress, and antioxidant nutrients.

Authors:  Lisa M Gaetke; Ching Kuang Chow
Journal:  Toxicology       Date:  2003-07-15       Impact factor: 4.221

10.  Hepatolenticular degeneration; Wilson's disease; a report of five cases, with commentary.

Authors:  C G WARNOCK
Journal:  Ulster Med J       Date:  1952-11-01
View more
  6 in total

1.  Acute-Onset Visual Impairment in Wilson's Disease: A Case Report and Literature Review.

Authors:  Zi-Wei Zheng; Meng-Hui Xu; Chuan-Bin Sun; Zhi-Ying Wu; Yi Dong
Journal:  Front Neurol       Date:  2022-06-14       Impact factor: 4.086

Review 2.  Practical insights into chronic management of hepatic Wilson's disease.

Authors:  Erica Nicola Lynch; Claudia Campani; Tommaso Innocenti; Gabriele Dragoni; Paolo Forte; Andrea Galli
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

Review 3.  Spur cell anemia related to alcoholic liver cirrhosis managed without liver transplantation: a case report and literature review.

Authors:  Takao Miwa; Yuichiro Hatano; Takahiro Kochi; Masashi Aiba; Katsuhisa Toda; Hideko Goto; Noriaki Nakamura; Naoki Katsumura; Kenji Imai; Masahito Shimizu
Journal:  Clin J Gastroenterol       Date:  2020-05-29

4.  Human Embryonic Stem Cell-Derived Wilson's Disease Model for Screening Drug Efficacy.

Authors:  Dongkyu Kim; Su-Bin Kim; Jung Lim Ryu; Heesu Hong; Jin-Hyuk Chang; Tack-Jin Yoo; Xiong Jin; Han-Jin Park; Choongseong Han; Beom Hee Lee; Jin-Ho Choi; Han-Wook Yoo; Jong-Hoon Kim; Dong-Hun Woo
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

5.  A population-based epidemiology of Wilson's disease in South Korea between 2010 and 2016.

Authors:  Eun Ju Choe; Jong Won Choi; Minjin Kang; Yong Kang Lee; Han Ho Jeon; Byung Kyu Park; Sun Young Won; Yong Suk Cho; Jeong Hun Seo; Chun Kyon Lee; Jae Bock Chung
Journal:  Sci Rep       Date:  2020-08-20       Impact factor: 4.379

6.  Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series.

Authors:  Oriol De Fabregues; Jaume Viñas; Antoni Palasí; Manuel Quintana; Ignasi Cardona; Cristina Auger; Víctor Vargas
Journal:  Brain Behav       Date:  2020-03-22       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.